Antibody-cell-conjugation (ACC) technology enables the modification of cell surfaces with single-strand DNA (ssDNA). The modified cells are further annealed with the complementary strand-modified molecules. The ACC platform has been applied to link NK cells with transtuzumab (anti-HER2 mAb), allowing oNK cells (NK-92 cell line) to efficiently target HER2-expressing cancer cells in vitro and in vivo. Here, ERBB2 is linked to cancer.